Relevance of high-dose chemotherapy in solid tumours

Cancer Treatment Reviews

Volumn 31, Issue 3, 2005, Pages 210-225

  Nieboer, P ^a   de Vries, E G E ^a   Mulder, N H ^a   van der Graaf, W T A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

High dose chemotherapy; Solid tumours

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PLATINUM DERIVATIVE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE; THIOTEPA; TRASTUZUMAB;

ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CHILDHOOD CANCER; CLINICAL TRIAL; DIARRHEA; DRUG MEGADOSE; EARLY MENOPAUSE; EWING SARCOMA; FATIGUE; GRANULOCYTOPENIA; HEMORRHAGIC CYSTITIS; HUMAN; INFERTILITY; KIDNEY DYSFUNCTION; LEUKEMIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MUCOSA INFLAMMATION; MYELODYSPLASIA; NAUSEA; NEUROECTODERM TUMOR; OTOTOXICITY; OVARY CANCER; PERIPHERAL NEUROPATHY; PSYCHOPATHY; REVIEW; SECOND CANCER; SOFT TISSUE SARCOMA; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 20344362900     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2005.02.002     Document Type: Article

References (101)

1. R.B. Weiss G.G. Gill C.A. Hudis An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications J Clin Oncol 19 2001 2771-2777
2. R.B. Weiss R.M. Rifkin F.M. Stewart et al. High-dose chemotherapy for high-risk primary breast cancer: An on-site review of the Bezwoda study Lancet 355 2000 999-1003
3. S. Rodenhuis M. Bontenbal L.V. Beex et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med 349 2003 7-16
4. H.H. Roche P. Pouillart N. Meyer et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N > 7) breast cancer patients: The Pegase 01 Trial Proc Am Soc Clin Oncol 2001 abstract 102
5. U.A. Nitz M. Frick S. Mohrmann et al. Tandem high dose chemotherapy versus dose-dense conventional chemotherapy for patients with high risk breast cancer: Interim results from a multicenter phase III trial Proc Am Soc Clin Oncol 2003 abstract 3344
6. E. Frei III G.P. Canellos Dose: A critical factor in cancer chemotherapy Am J Med 69 1980 585-594
7. E. Frei III C.A. Cucchi A. Rosowsky et al. Alkylating agent resistance: in vitro studies with human cell lines Proc Natl Acad Sci USA 82 1985 2158-2162
8. F.M. Schabel Jr. M.W. Trader W.R. Laster Jr. G.P. Wheeler M.H. Witt Patterns of resistance and therapeutic synergism among alkylating agents Antibiot Chemother 23 1978 200-215
9. B.A. Teicher S.A. Holden C.A. Cucchi et al. Combination of N,N′,N-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo Cancer Res 48 1988 94-100
10. E. Frei III B.A. Teicher S.A. Holden et al. Preclinical studies and clinical correlation of the effect of alkylating dose Cancer Res 48 1988 6417-6423
11. W. Hryniuk H. Bush The importance of dose intensity in chemotherapy of metastatic breast cancer J Clin Oncol 2 1984 1281-1288
12. W. Hryniuk M.N. Levine Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J Clin Oncol 4 1986 1162-1170
13. L. Levin W.M. Hryniuk Dose intensity analysis of chemotherapy regimens in ovarian carcinoma J Clin Oncol 5 1987 756-767
14. H.M. Lazarus M.D. Reed T.R. Spitzer et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer Cancer Treat Rep 71 1987 689-695
15. J.O. Armitage Bone marrow transplantation N Engl J Med 330 1994 827-838
16. J. Beyer N. Schwella J. Zingsem et al. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison J Clin Oncol 13 1995 1328-1335
17. J. Bergh T. Wiklund B. Erikstein et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study Lancet 356 2000 1384-1391
18. S. Fetscher J. Finke R. Engelhardt et al. Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation Ann Hematol 74 1997 73-77
19. N. Kroger A.R. Zander G. Martinelli et al. Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: A study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation Ann Oncol 14 2003 554-558
20. M.S. Tallman R. Gray N.J. Robert et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 2003 17-26
21. W.R. Bezwoda L. Seymour R.D. Dansey High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial J Clin Oncol 13 1995 2483-2489
22. E.A. Stadtmauer A. O'Neill L.J. Goldstein et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group N Engl J Med 342 2000 1069-1076
23. E.A. Stadtmauer A. O'Neill L.J. Goldstein et al. Conventional-dose chemotherapy compared with high-dose chemotherapy (HDC) plus autologous stem-cell transplantation (SCT) for metastatic breast cancer: 5-year update of the Philadelphia trial (PBT-1) Proc Am Soc Clin Oncol 2002 abstract 169
24. W.P. Peters R.B. Jones J.J. Vredenburgh et al. A large, prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction chemotherapy (AFM) Proc Am Soc Clin Oncol 1996 abstract 149
25. J.-P. Lotz H. Curé M. Janvier et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol Pegase 04 Proc Am Soc Clin Oncol 1999 abstract 161
26. P. Biron M. Durand H. Roche et al. High-dose thiotepa (TTP), cyclophosphamide (CPM) and stem cell transplantation after 4 FEC 100 compared with 4 FEC alone allowed a better disease free survival but the same overall survival in first line chemotherapy for metastatic breast cancer. Results of the PEGASE 03 French Protocole Proc Am Soc Clin Oncol 2002 abstract 167
27. J.P. Crown L. Perey M. Lind et al. Superiority of tandem high-dose chemotherapy (HDC) versus optimized conventionally-dosed chemotherapy (CDC) in patients (pts) with metastatic breast cancer (MBC): The International Randomized Breast Cancer Dose Intensity Study (IBDIS 1) Proc Am Soc Clin Oncol 2003 abstract 88
28. D.A. Berry G. Broadwater J.P. Klein et al. High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry J Clin Oncol 20 2002 743-750
29. Y. Nieto S. Nawaz R.B. Jones et al. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer J Clin Oncol 20 2002 707-718
30. S.E. Singletary C. Allred P. Ashley et al. Revision of the American Joint Committee on Cancer staging system for breast cancer J Clin Oncol 20 2002 3628-3636
31. R.A. Brito V. Valero A.U. Buzdar et al. Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience J Clin Oncol 19 2001 628-633
32. R.B. Weiss S.H. Woolf E. Demakos et al. Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: A study by the Cancer and Leukemia Group B J Clin Oncol 21 2003 1825-1835
33. W.R. Bezwoda Randomised, controlled trial of high-dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high-risk, surgically treated, primary breast cancer Proc Am Soc Clin Oncol 1999 abstract 4
34. G.N. Hortobagyi A.U. Buzdar R.L. Theriault et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma J Natl Cancer Inst 92 2000 225-233
35. S. Rodenhuis D.J. Richel E. Van der Wall et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 352 1998 515-521
36. A.R. Zander N. Kroger C. Schmoor et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: First results of a randomized trial J Clin Oncol 2004
37. R.C. Leonard M. Lind C. Twelves et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: A randomized trial J Natl Cancer Inst 96 2004 1076-1083
38. A. Gianni G. Bonadonna Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN) Proc Am Soc Clin Oncol 2001 abstract 80
39. Y. Tokuda T. Tajima M. Narabayashi et al. Randomized phase III study of high-dose chemotherapy (HDC) with autologous stem cell support as consolidation in high-risk postoperative breast cancer: Japan Clinical Oncology Group (JCOG9208) Proc Am Soc Clin Oncol 2001 abstract 148
40. J.M. Bliss D. Vigushin E. Kanfer et al. Randomised trial of high dose therapy using cyclophosphamide, thiotepa and carboplatin in primary breast cancer patients with 4 or more histologically involved positive nodes (ISRCTN: 52623943) Proc Am Soc Clin Oncol 2003 abstract 58
41. R. Basser A. O'Neill G. Martinelli et al. Randomized trial comparing up-front, multi-cycle dose-intensive chemotherapy (CT) versus standard dose CT in women with high-risk stage 2 or 3 breast cancer (BC): First results from IBCSG Trial 15-95 Proc Am Soc Clin Oncol 2003 abstract 20
42. J.G. Schrama I.F. Faneyte J.H. Schornagel et al. Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: Final analysis with 7 years of follow-up Ann Oncol 13 2002 689-698
43. J. Bergh Long-term follow-up of the randomized Scandinavian Breast Group (SBG) study 9401 comparing standard FEC followed by marrow supported high dose therapy versus tailored and dose-escalated FEC therapy Proc Am Soc Clin Oncol 2003 abstract 94
44. W.P. Peters A prospective, randomized comparison of two doses of alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 Proc Am Soc Clin Oncol 1999 abstract 2
45. D. Nikcevich J.J. Vredenburgh G. Broadwater et al. Ten year follow-up after high-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer Proc Am Soc Clin Oncol 2002 abstract 1657
46. G. Bonadonna P. Valagussa A. Moliterni et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node- positive breast cancer: The results of 20 years of follow-up N Engl J Med 332 1995 901-906
47. A. Harstrick H.J. Schmoll H. Wilke et al. Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma J Clin Oncol 9 1991 1549-1555
48. P.J. Loehrer Sr. R. Gonin C.R. Nichols et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 16 1998 2500-2504
49. J.A. McCaffrey M. Mazumdar D.F. Bajorin et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival J Clin Oncol 15 1997 2559-2563
50. C.R. Nichols G. Tricot S.D. Williams et al. Dose-intensive chemotherapy in refractory germ cell cancer - a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation J Clin Oncol 7 1989 932-939
51. S. Bhatia R. Abonour P. Porcu et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer J Clin Oncol 18 2000 3346-3351
52. E.R. Broun C.R. Nichols G. Gize et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer Cancer 79 1997 1605-1610
53. A. Gerl C. Clemm N. Schmeller et al. Prognosis after salvage treatment for unselected male patients with germ cell tumours Br J Cancer 72 1995 1026-1032
54. D. Josefsen S. Ous J. Hoie et al. Salvage treatment in male patients with germ cell tumours Br J Cancer 67 1993 568-572
55. S.B. Saxman C.R. Nichols L.H. Einhorn Salvage chemotherapy in patients with extragonadal nonseminomatous germ cell tumors: The Indiana University experience J Clin Oncol 12 1994 1390-1393
56. J. Beyer S. Stenning A. Gerl et al. High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: A matched-pair analysis Ann Oncol 13 2002 599-605
57. D.A. Vaena R. Abonour L.H. Einhorn Long-term survival after high-dose salvage chemotherapy for germ-cell malignancies with adverse prognostic variables Proc Am Soc Clin Oncol 2003 abstract 1538
58. G. Rosti J.L. Pico H. Wandt et al. High-dose chemotherapy (HDC) in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors (GCT); first results of a prospective randomised trial of the European Group for Blood and Marrow Transplantation (EBMT): IT-94 study Proc Am Soc Clin Oncol 2002 abstract 716
59. S. Rodenhuis R. de Wit P.H. de Mulder et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission Ann Oncol 10 1999 1467-1473
60. L.J. Ayash M. Clarke S.M. Silver et al. Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: The University of Michigan experience and literature review Bone Marrow Transplant 27 2001 939-947
61. B.K. Margolin J.H. Doroshow C. Ahn et al. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support J Clin Oncol 14 1996 2631-2637
62. R.J. Motzer M. Mazumdar J. Sheinfeld et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients J Clin Oncol 18 2000 1173-1180
63. O. Rick C. Bokemeyer J. Beyer et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer J Clin Oncol 19 2001 81-88
64. J. Shamash C.A. O'Doherty R.T. Oliver et al. Should high-dose chemotherapy be used to consolidate second or third line treatment in relapsing germ cell tumours? Acta Oncol 39 2000 857-863
65. A.C. Donadio J. Sheinfeld J. Bacik et al. Paclitaxel, ifosfamide, and cisplatin (TIP): An effective second-line therapy for patients (pts) with relapsed testicular germ cell tumors (GCT Proc Am Soc Clin Oncol 2003 abstract 1537
66. C. Bokemeyer A. Harstrick J. Beyer et al. The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group Semin Oncol 25 1998 24-32
67. M.P. Decatris P.M. Wilkinson R.S. Welch et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: An effective first-line therapy with minimal toxicity Ann Oncol 11 2000 427-434
68. C. Bokemeyer C. Kollmannsberger C. Meisner et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis J Clin Oncol 17 1999 3450-3456
69. C. Chevreau J.P. Droz J.L. Pico et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial Eur Urol 23 1993 213-217
70. S.E. Grenman V.T. Rantanen T.A. Salmi High-dose chemotherapy with autologous stem cell support in advanced ovarian cancer Ann Med 28 1996 151-158
71. E.G. de Vries T.C. Hamilton M. Lind et al. Advanced ovarian cancer. Drug resistance, supportive care and dose intensity Ann Oncol 4 Suppl 4 1993 57-62
72. P.J. Stiff R. Bayer C. Kerger et al. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients J Clin Oncol 15 1997 1309-1317
73. P.J. Stiff J. Veum-Stone H.M. Lazarus et al. High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: An autologous blood and marrow transplant registry report Ann Intern Med 133 2000 504-515
74. J.A. Ledermann R. Herd D. Maraninchi et al. High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT) Ann Oncol 12 2001 693-699
75. E. Pujade-Lauraine H. Cure C. Battista et al. High dose chemotherapy in ovarian cancer Int J Gynecol Cancer 11 Suppl 1 2001 64-67
76. H. Cure C. Battista J.P. Guastalla et al. Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): Preliminary results of a GINECO/ FNCLCC/ SFGM-TC study Proc Am Soc Clin Oncol 2001 abstract 815
77. N. Lucidarme D. Valteau-Couanet O. Oberlin et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors Bone Marrow Transpl 22 1998 535-540
78. C. Bokemeyer A. Franzke J.T. Hartmann et al. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas Cancer 80 1997 1221-1227
79. C. Dumontet P. Biron E. Bouffet et al. High dose chemotherapy with ABMT in soft tissue sarcomas: A report of 22 cases Bone Marrow Transpl 10 1992 405-408
80. A.D. Elias L.J. Ayash J.P. Eder et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support J Clin Oncol 9 1991 320-327
81. R. Mesia C. Sola P.A. Lopez et al. High-dose chemotherapy and autologous bone marrow transplantation in high-grade metastatic sarcomas Rev Clin Esp 194 1994 960-965
82. J.Y. Blay D. Bouhour I. Ray-Coquard et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults J Clin Oncol 18 2000 3643-3650
83. A. Atra J.S. Whelan V. Calvagna et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma Bone Marrow Transpl 20 1997 843-846
84. S. Burdach H. Jurgens C. Peters et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma J Clin Oncol 11 1993 1482-1488
85. S. Burdach B. van Kaick H.J. Laws et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria Ann Oncol 11 2000 1451-1462
86. O. Hartmann O. Oberlin F. Beaujean et al. Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children Bull Cancer 77 1990 181-187
87. M.E. Horowitz T.J. Kinsella L.H. Wexler et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma J Clin Oncol 11 1993 1911-1918
88. P.J. Souquet F. Chauvin J.P. Boissel et al. Polychemotherapy in advanced non small cell lung cancer: A meta-analysis Lancet 342 1993 19-21
89. S. Fetscher W. Brugger R. Engelhardt et al. Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 107 consecutive patients with limited- and extensive-stage non-small-cell lung cancer Ann Oncol 8 1997 57-64
90. Y. Humblet M. Symann A. Bosly et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: A randomized study J Clin Oncol 5 1987 1864-1873
91. P. Lorigan P. Woll M. O'Brien et al. Randomised phase 3 trial of dose dense ICE chemotherapy versus standard ICE in good prognosis small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 2003 abstract 2490
92. C.B. Pratt S. Epelman N. Jaffe Bleomycin, cyclophosphamide, and dactinomycin in metastatic osteosarcoma: Lack of tumor regression in previously treated patients Cancer Treat Rep 71 1987 421-423
93. F. Fagioli M. Aglietta A. Tienghi et al. High-dose chemotherapy in the treatment of relapsed osteosarcoma: An Italian sarcoma group study J Clin Oncol 20 2002 2150-2156
94. C. Linassier M. Ben Hassel D. Figarella-Branger et al. Phase III study comparing high-dose BCNU with autologous blood stem cell support versus standard dose BCNU, in combination with radiotherapy after gross total resection in patients with supratentorial glioblastoma Proc Am Soc Clin Oncol 2003
95. K.K. Matthay J.G. Villablanca R.C. Seeger et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group N Engl J Med 341 1999 1165-1173
96. M. Al Hajj M.S. Wicha A. Benito-Hernandez et al. Prospective identification of tumorigenic breast cancer cells Proc Natl Acad Sci USA 100 2003 3983-3988
97. M.J. van de Vijver Y.D. He L.J. van't Veer et al. A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 2002 1999-2009
98. A.D. Elias J. Ibrahim P. Richardson et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: An analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program Biol Blood Marrow Transpl 8 2002 198-205
99. M. Bregni A. Dodero J. Peccatori et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer Blood 99 2002 4234-4236
100. P. Pedrazzoli G.A. Da Prada G. Giorgiani et al. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: A pilot study in patients with refractory malignancies Cancer 94 2002 2409-2415
101. N.T. Ueno G. Rondon N.Q. Mirza et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer J Clin Oncol 16 1998 986-993